The dysfunctional nature of CD34 + cells from patients with heart failure (HF) may make them unsuitable for autologous stem-cell therapy. In view of evidence that the vasoprotective axis of the renin-angiotensin system (RAS) improves CD34 + cell functions, we hypothesized that CD34 + cells from patients with HF will be dysfunctional and that angiotensin-(1-7) [Ang-(1-7)] would improve their function. Peripheral blood was collected from New York Heart Association class II-IV patients with HF (n = 31) and reference subjects (n = 16). CD34 + cell numbers from patients with HF were reduced by 47% (P , 0.05) and also displayed 76% reduction in migratory capacity and 56% (P , 0.05) lower production of nitric oxide. These alterations were associated with increases in RAS genes angiotensin-converting enzyme and AT2R (595%, P , 0.05) mRNA levels and 80% and 85% decreases in angiotensin-converting enzyme 2 and Mas mRNA levels, respectively. Treatment with Ang-(1-7) enhanced CD34 + cell function through increased migratory potential and nitric oxide production, and reduced reactive oxygen species generation. These data show that HF CD34 + cells are dysfunctional, and Ang-(1-7) improves their functions. This suggests that activation of the vasoprotective axis of the RAS may hold therapeutic potential for autologous stemcell therapy in patients with HF.
INTRODUCTION
Heart failure (HF) remains a major cause of morbidity and mortality, despite recent advances in the treatment of acute and chronic cardiac events. 1 Consequently, development of novel therapies for HF is critical. Recently, the benefits of autologous stem-cell therapy for treatment of HF have been investigated. 2 Thus far, the clinical trial results have been inconsistent, 3 but these moderate results may be attributed to technological hurdles 4, 5 or dysfunctional autologous progenitor cells. 6 CD34 + hematopoietic stem cells have been studied about their role in cardiac repair during HF. CD34 + cells play a vital role in vascular maintenance 7 and cardiac repair. 8 In humans, CD34 + cell numbers have been shown to decline with increasing HF severity 9 and correlate with cardiovascular risk. 10 Importantly, previous studies have reported impaired function of CD34 + cells in patients with ischemic cardiomyopathy 11 or vascular complications from diabetes. [12] [13] [14] Collectively, these data suggest that CD34 + cells contribute to cardiovascular health and that their dysfunction during disease may compromise their utility in autologous stem-cell transfer.
In this regard, the recent discovery of the vasoprotective axis of the renin-angiotensin system (RAS) is relevant. It is composed of angiotensin-converting enzyme 2 (ACE2), angiotensin 1-7 (Ang 1-7), and Mas receptor which acts as a balance for the vasodeleterious RAS axis [ACE/Angiotensin II (Ang II)/Angiotensin type 1 Receptor (AT1R)]. Although the vasodeleterious axis has long been implicated in cardiovascular disease, studies have demonstrated that a shift toward the vasoprotective axis shows benefits to the heart. 15 The beneficial effects of Ang-(1-7), the effector peptide of the vasoprotective RAS, on CD34 + cells are currently under investigation, and the outcomes to this point have been promising. 16, 17 Thus, we propose to study the ability of Ang-(1-7) to enhance the function of CD34 + cells from patients with HF.
METHODS

Patient Selection and Characterization
Peripheral blood was collected from New York Heart Association (NYHA) class II-IV patients with HF and from reference subjects (controls). This study was conducted under approval from the institutional review board of the University of Florida. Participants gave written informed consent to participate in this study, and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. Patients were consented to participate if they met the following criteria: older than 18 years, significant coronary artery disease (70% luminal diameter narrowing of at least 1 major coronary artery), left ventricular ejection fraction ,45% limiting angina (class II-IV), and/or congestive HF (NYHA class II-IV), on maximal medical therapy for angina symptoms, and hemodynamically stable as defined by a systolic blood pressure greater than 80 mm Hg. Patients were excluded from this study if they had atrial fibrillation, atrial flutter and/or uncontrolled arrhythmias, left ventricular thrombus, platelet count M ,100 k/mm 3 , white blood cells ,2 k/mm 3 , stroke within 60 days of study enrollment, history of malignancy in the past 5 years, history of HIV, hepatitis B or C, or hepatic dysfunction as defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) B.1.5 times the upper limit of normal. Pertinent characteristics of the patients are described in Table 1 . All patients were dosed to the highest tolerated or maximal approved therapies as recommended in the ACC/AHA Heart Failure Guidelines. Control subjects were ages 39 6 13.
Isolation of Human CD34 + Cells
Peripheral blood was collected from patients with HF (n = 30) or reference subjects (n = 16) using blood collection tubes with EDTA (Thermo Fisher Scientific, Waltham, MA), and CD34 + cells were isolated as described previously. 14 It is critical to note that the amount of blood, and thus CD34 + cells, from each patient was highly variable and that the number of CD34 + cells from many patients was severely limited. As a result, we were not able to perform all experiments with all patient samples.
Quantification of CD34 + Cells From Whole Blood
Within 24 hours of blood collection, 100 mL of blood from each donor were used to count CD34 + cells by BD Procount progenitor cell enumeration kit (BD Biosciences, San Jose, CA) per manufacturer instructions followed by analysis on a LSR II flow cytometer (BD Biosciences) with FCS Express (BD Biosciences).
Cell Migration Assay CD34 + cell migration toward 100 nM stromal cellderived factor 1a (SDF-1a; R&D Systems, Minneapolis, MN) or phosphate-buffered saline for 4 hours at 378C was measured using the QCM Chemotaxis 5 mm Migration Chamber (Millipore, Billerica, MA) according to manufacturer instructions and as previously described. 18 For determination of the effects of Ang-(1-7) on migration, freshly isolated CD34 + cells were pretreated with 100 nM Ang-(1-7) (Bachem, Bubendorf, Switzerland) for 1 hour before following the protocol above. This concentration of Ang-(1-7) was selected based on a preliminary doseresponse experiment and previous experience with treatment of CD34 + cells with Ang-(1-7) in vitro. 16 
Measurement of Nitric Oxide Production
Nitric oxide (NO) levels in CD34 + cells were measured by fluorescence intensity of DAF-FM (Thermo Fisher Scientific) as described previously. 19 Briefly, 20,000 CD34 + cells were incubated with 20 mM DAF-FM for 30 minutes in the dark followed by the addition of 1 mM L-arginine and stimulant [100 nM SDF-1a or 100 nM Ang-(1-7)] for 30 minutes and fluorescence was measured at 485 nm (excitation) and 528 nm (emission).
Measurement of Reactive Oxygen Species
Basal levels of reactive oxygen species (ROS) production were measured using dihydroethidium (DHE; SigmaAldrich, St. Louis, MO). Briefly, 20,000 freshly isolated CD34 + cells (in triplicate) were incubated with 5 mM DHE in Dulbecco's phosphate-buffered saline with Ca 2+ and Mg 2+ supplemented with 1 mg/mL glucose for 15 minutes in the dark. For some cells, Ang-(1-7) was subsequently added at a final concentration of 100 nM for 30 minutes, followed by measurement of fluorescence at 488 nm (excitation) and 585 nm (emission).
Gene Expression by Real-Time RT-PCR
Total RNA was extracted from CD34 + cells and quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed as described previously. 14 Data presented as mean 6 SEM, and n represents the number of donors used. Percentage of patients within each category are noted in parentheses.
FAM-labeled primers (Applied Biosystems, Foster City, CA) were used: ACE (Hs01104600_m1), ACE2 (Hs01085333_m1), Mas (Hs00267157_s1), and AT2R (Hs00169126_m1). All samples were run in duplicate and normalized to 18s (Hs99999901_s1) cDNA.
Statistical Analyses
All results are presented as mean 6 standard error of the mean (SEM). To compare between 2 groups, Student's t test was performed. For comparison between 3 or more groups, 1-way analysis of variance followed by Tukey's post hoc test was performed. The statistical analyses were performed using GraphPad Prism5 (GraphPad Software, Inc, La Jolla, CA). P , 0.05 was considered as significant.
RESULTS
Patients With HF Exhibit Reduced Number and Impaired Function of CD34 + Cells
We demonstrated that the absolute number of CD34 + cells in whole blood was reduced by 47% in patients with HF (2.98 6 1.5 cells/mL blood vs. controls: 5.59 6 0.5 cells/mL of blood, P , 0.05, Fig. 1A ). We then determined if there were differences in the function of HF CD34 + cells. Patient with HF CD34 + cells demonstrated 76% reduction in migratory response to SDF-1a compared with CD34 + cells from reference donors (9.71 6 8.6% increase toward SDF-1a in HF vs. 40 6 15.9% increase toward SDF-1a in controls; P , 0.05; Fig. 1B ). Basal NO levels in CD34 + cells from patients with HF were 34% lower than that in control CD34 + cells [5192 6 406.3 relative fluorescence units (RFU) in control vs. 3448.4 6 184.1 RFU in HF; P , 0.001, Fig. 1C ]. In addition, NO bioavailability in response to SDF-1a was reduced by 56% in patient with HF CD34 + cells (47.7 6 4.5 RFU in control vs. 21.1 6 12.5 RFU in HF; P , 0.05, Fig. 1D ). Furthermore, basal levels of ROS tended to be 69% higher in CD34 + cells from patients with HF (1036.3 6 184.6 RFU in control vs. 1755.9 6 874.7 RFU in HF; Fig. 1E ).
CD34 + Cells from Patients With HF Display Altered RAS Gene Expression
Given the involvement of the RAS in the development of cardiovascular disease, we measured the mRNA levels of key members of the RAS. ACE was undetectable in control cells but trended toward an increase in HF CD34 + cells (2 2dCt : 1.66 · 10 24 , Fig. 2A Fig. 2D ).
Ang-(1-7) Improves Migratory Ability, NO Bioavailability, and ROS Production of CD34 + Cells Next, we were interested if incubation with Ang-(1-7) would restore the reparative capabilities of CD34 + cells. Pretreatment of CD34 + cells with Ang- (1-7) improved the SDF1a-induced migratory abilities of CD34 + cells from both controls (147% increase, Fig. 2E ) and patients with HF (89% increase, Fig. 2F ). In addition, pretreatment of CD34 + cells with Ang-(1-7) increased NO production by 6.8% in CD34 + cells from controls and 15.3% in (Fig. 2G ) those from patients with HF. It is interesting to note that although basal NO levels FIGURE 1. CD34 + cells from patients with HF are dysfunctional. A, Fluorescence-activated cell sorting analysis of the absolute number of CD34 + cells per mL of whole blood (n = 4-9). B, Migratory response of CD34 + cells toward SDF-1a (n = 7-13). C, Basal (n = 3-4) and (D) SDF-1a-induced NO (n = 8-9) production assessed by DAF-FM fluorescence. E, Basal ROS levels measured by DHE fluorescence (n = 4-5). Data are presented as mean 6 SEM. *P , 0.05.
were lower in patient with HF CD34 + cells than controls (Fig. 1C) , CD34 + cells from patients with HF exhibited a more robust response to Ang-(1-7) treatment. Last, we found that Ang-(1-7) treatment reduced ROS production by 12% in CD34 + cells from both patients with HF and controls (Fig. 2H) .
DISCUSSION
This study demonstrates that ex vivo pretreatment of CD34 + cells with Ang-(1-7) enhances crucial functional capabilities of the CD34 + cells isolated from both patients with HF and reference individuals. In particular, our study highlights the molecular changes in the RAS of CD34 + cells from patients with HF, which may underlie some of the pathologies induced during HF. Previous studies have shown imbalance in RAS components in the heart and brain during HF. [20] [21] [22] [23] Our group has also demonstrated that diabetic patients have dysfunctional CD34 + cells with reduced ACE2 mRNA expression. 16 However, to the best of our knowledge, we are the first to report alterations in the vasoprotective and vasodeleterious axes of the RAS in CD34 + cells from patients with HF. Specifically, HF CD34 + cells exhibited increases in ACE and AT2R mRNA expression and decreases in the expression of ACE2 and Mas. Whether these changes are causative of CD34 + cell dysfunction that remains to be investigated.
The most critical aspect of our study is the demonstration that treatment of CD34 + cells with Ang-(1-7) enhances CD34 + cell function. It is well known that Ang-(1-7) has anti-inflammatory, antifibrotic, and vasodilatory properties, and it is also associated with NO release and attenuation of oxidative stress. 24 Furthermore, Ang-(1-7) improves cardiac function in different animal models of HF. 25, 26 In this study, our data suggest that these cardioprotective effects of Ang-(1-7) may be, in part, a result of its actions on CD34 + cells.
This study is a proof-of-concept that manipulation of the vasoprotective RAS may enhance the function of CD34 + cells for treatment of HF. However, there are caveats to this study that need to be addressed before such treatment may be possible. First, low patient and cell numbers prohibited us from performing every test with cells from each donor and from reporting results separately for each NYHA class. Having more patients in each category would have allowed us to determine if these measures of dysfunction are progressive, and if dysfunction in any of these parameters precedes the dysfunction of the others. Second, we have shown here that CD34 + cell function can be improved by incubation with Ang- (1-7) . However, the amount of time cells spent incubated with Ang-(1-7) here was relatively short, and the parameters tested were in vitro. It remains to be seen what in vivo effects, if any, CD34 + cells treated in vitro would have and how this may change with longer treatment with Ang- (1-7) . Nevertheless, the discoveries made here show strong potential for solving one of the major limitations for autologous stem-cell therapy through the treatment of CD34 + cells with Ang-(1-7).
CONCLUSIONS
Incubation of CD34 + cells with Ang-(1-7) enhances crucial functional capabilities of CD34 + cells isolated from both patients with HF and reference individuals. The use of Ang-(1-7) pretreatment of CD34 + cells may be a valuable strategy before autologous cell therapy in patients with HF.
